Poly (ADP-ribose) polymerase inhibitors: recent advances and future development
Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with delete...
Saved in:
Published in | Journal of clinical oncology Vol. 33; no. 12; pp. 1397 - 1406 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society of Clinical Oncology
20.04.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!